Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zhu, W.
Right arrow Articles by Young, C. Y.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, W.
Right arrow Articles by Young, C. Y.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 9, 1399-1403, September 2001
© 2001 Oxford University Press

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP

Wen Zhu, Jin-San Zhang and Charles Y.F. Young,1

Department of Biochemistry and Molecular Biology and Department of Urology, Mayo Graduate School, Mayo Clinic/Foundation, Rochester, MN 55905, USA

A number of reports have shown that the polyphenolic flavonoid silymarin (SM) is an effective anticancer agent. Agents with novel mechanisms of blocking androgen receptor (AR) function may be useful for prostate cancer prevention and therapy. Previous studies showed that silibinin (SB), the major active component of SM, could inhibit cell proliferation of a human prostate cancer cell line, LNCaP, by arresting the cell cycle at the G1 phase without causing cell death. This study further delineates the potential molecular mechanism by which SM and SB exhibit antiproliferative effects on androgen-responsive prostate cancer cells by inhibiting function of the AR. We observed that SM and SB inhibited androgen-stimulated cell proliferation as well as androgen-stimulated secretion of both prostate-specific antigen (PSA) and human glandular kallikrein (hK2). Additionally, for the first time, we show that an immunophilin, FKBP51, is androgen regulated and that this up-regulation is suppressed by SM and SB. We further demonstrate that transactivation activity of the AR was diminished by SM and SB using gene transfer of PSA promoter and hK2 androgen-responsive element constructs. However, expression and steroid-binding ability of total AR were not affected by SM in western blotting and ligand-binding assays. Intriguingly, we found that nuclear AR levels are significantly reduced by SM and SB in the presence of androgens using western blotting assay and immunocytochemical staining. This study provides a new insight into how SM and SB negatively modulate androgen action in prostate cancer cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
M. B. Cox, D. L. Riggs, M. Hessling, F. Schumacher, J. Buchner, and D. F. Smith
FK506-Binding Protein 52 Phosphorylation: A Potential Mechanism for Regulating Steroid Hormone Receptor Activity
Mol. Endocrinol., December 1, 2007; 21(12): 2956 - 2967.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. N. Syed, N. Khan, F. Afaq, and H. Mukhtar
Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2193 - 2203.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Periyasamy, M. Warrier, M. P. M. Tillekeratne, W. Shou, and E. R. Sanchez
The Immunophilin Ligands Cyclosporin A and FK506 Suppress Prostate Cancer Cell Growth by Androgen Receptor-Dependent and -Independent Mechanisms
Endocrinology, October 1, 2007; 148(10): 4716 - 4726.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Deep, N. H. Oberlies, D. J. Kroll, and R. Agarwal
Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells
Carcinogenesis, July 1, 2007; 28(7): 1533 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
G. Deep and R. Agarwal
Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer
Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
W. Yong, Z. Yang, S. Periyasamy, H. Chen, S. Yucel, W. Li, L. Y. Lin, I. M. Wolf, M. J. Cohn, L. S. Baskin, et al.
Essential Role for Co-chaperone Fkbp52 but Not Fkbp51 in Androgen Receptor-mediated Signaling and Physiology
J. Biol. Chem., February 16, 2007; 282(7): 5026 - 5036.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. P Singh and R. Agarwal
Mechanisms of action of novel agents for prostate cancer chemoprevention.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Zhang, X.-W. Wang, D. Jelovac, T. Nakanishi, M.-h. Yu, D. Akinmade, O. Goloubeva, D. D. Ross, A. Brodie, and A. W. Hamburger
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells
PNAS, July 12, 2005; 102(28): 9890 - 9895.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. R. Davis-Searles, Y. Nakanishi, N.-C. Kim, T. N. Graf, N. H. Oberlies, M. C. Wani, M. E. Wall, R. Agarwal, and D. J. Kroll
Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells
Cancer Res., May 15, 2005; 65(10): 4448 - 4457.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Bonham, J. Posakony, I. Coleman, B. Montgomery, J. Simon, and P. S. Nelson
Characterization of Chemical Constituents in Scutellaria baicalensis with Antiandrogenic and Growth-Inhibitory Activities toward Prostate Carcinoma
Clin. Cancer Res., May 15, 2005; 11(10): 3905 - 3914.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. M. Velasco, K. A. Gillis, Y. Li, E. L. Brown, T. M. Sadler, M. Achilleos, L. M. Greenberger, P. Frost, W. Bai, and Y. Zhang
Identification and Validation of Novel Androgen-Regulated Genes in Prostate Cancer
Endocrinology, August 1, 2004; 145(8): 3913 - 3924.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. Pan, J.-S. Zhang, M. H. Gazi, and C. Y. F. Young
The Cyclooxygenase 2-specific Nonsteroidal Anti-inflammatory Drugs Celecoxib and Nimesulide Inhibit Androgen Receptor Activity via Induction of c-Jun in Prostate Cancer Cells
Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 769 - 774.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. R. Hubler, W. B. Denny, D. L. Valentine, J. Cheung-Flynn, D. F. Smith, and J. G. Scammell
The FK506-Binding Immunophilin FKBP51 Is Transcriptionally Regulated by Progestin and Attenuates Progestin Responsiveness
Endocrinology, June 1, 2003; 144(6): 2380 - 2387.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. R. Sinars, J. Cheung-Flynn, R. A. Rimerman, J. G. Scammell, D. F. Smith, and J. Clardy
Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes
PNAS, February 4, 2003; 100(3): 868 - 873.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Zhang, J. Ni, E. M. Messing, E. Chang, C.-R. Yang, and S. Yeh
Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells
PNAS, May 28, 2002; 99(11): 7408 - 7413.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. Yanaida, H. Kohno, K. Yoshida, Y. Hirose, Y. Yamada, H. Mori, and T. Tanaka
Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats
Carcinogenesis, May 1, 2002; 23(5): 787 - 794.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.